Berger, the former vice president of Real World Data and Analytics at Pfizer, joins SHYFT to help guide the strategic growth and momentum of the company's software suite of Real-World Evidence products and solutions for Life Sciences.
Berger brings nearly 20 years of experience in outcomes, research, and analytics in Life Sciences. Most recently, he served as vice president of Real World Data and Analytics at Pfizer, where he led an enterprise wide center of excellence focused on RWE-driven collaboration, engagement, and quality improvement.
Prior to Pfizer, he served in a variety of leadership roles including vice president, Global Health Outcomes at Eli Lilly and vice president, Outcomes Research and Management at Merck.
SHYFT is an analytics cloud platform for life sciences with products and solutions designed specifically for the unique pharmaceutical, biotech, and medical device industry.
The company's Data Analytics Platform transforms healthcare data to accelerate commercial and clinical performance through converged insights. SHYFT is headquartered in Boston with offices in San Francisco and New York City.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon